XML 42 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 18, 2020
shares
Dec. 31, 2022
USD ($)
Reporting_Unit
Segment
$ / shares
shares
Dec. 31, 2021
USD ($)
shares
Mar. 31, 2020
shares
Summary Of Significant Accounting Policies [Line Items]        
Cash, cash equivalents and restricted cash, maturity period   three months or less    
Cash equivalents   $ 9,300,000 $ 9,300,000  
Financial assets transfers between level amount   0 0  
Financial liabilities transfers between level amount   $ 0 0  
Number of operating business segments | Segment   1    
Number of reporting units | Reporting_Unit   1    
Impairment charge   $ 48,648,000 0  
Impairments of long-lived assets   $ 0 $ 0  
Basic weighted average shares outstanding | shares   14,285,254 14,819,582  
Warrants exercise price | $ / shares   $ 0.001    
Antidilutive securities excluded from computation of earnings per share, amount | shares   8,139,155 1,087,174  
Tax benefit   $ 0    
Income tax examination, likelihood of settlement, description   The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.    
Income tax examination, likelihood of settlement, percentage   50.00%    
2014 Stock Incentive Plan [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Increase in number of shares of common stock authorized for issuance | shares       28,816
Common stock, number of shares initially reserved for issuance | shares   0    
Equity compensation period   10 years    
2014 Employee Stock Purchase Plan [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Increase in number of shares of common stock authorized for issuance | shares       7,204
Common stock, number of shares initially reserved for issuance | shares   24,077    
2020 Plan [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Common stock, number of shares initially reserved for issuance | shares 4,860,000 3,126,608    
Percentage of issued and outstanding shares of common stock 15.00%      
Equity compensation period 3 years      
Stock Options [Member] | Board of Directors [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Expected life assumption using simplified method, description   For stock options granted to the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account for the extended range of time of 12 to 18 months vested stock options granted to Board members may be exercised upon termination.    
Expected life assumption using simplified method   12 months    
Fair Value, Measurements, Recurring [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Assets measured at fair value   $ 0 $ 0  
Liabilities measured at fair value   $ 0 $ 0  
Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Expected life assumption using simplified method   6 years 6 months 6 years 9 months  
Maximum [Member] | Stock Options [Member] | Board of Directors [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Vesting period of stock options granted   18 months    
Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Expected life assumption using simplified method   6 years 3 months 6 years 3 months  
Minimum [Member] | Stock Options [Member] | Board of Directors [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Vesting period of stock options granted   12 months    
Warrants [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Basic weighted average shares outstanding | shares   509,117    
Anelixis [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Impairment charge   $ 48,600,000    
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.        
Summary Of Significant Accounting Policies [Line Items]        
Ownership interest percentage   100.00%    
Otic Pharma, Inc. [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Ownership interest percentage   100.00%